Approved medicineAprobado para usos específicosWADA
Community protocol · HGH / Somatropin
HGH / Somatropin: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: HGH · Human growth hormone · Somatropin
Sources checked: 27 August 2026
Aviso importante de seguridad y responsabilidad
Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
HGH / Somatropin
Sustituye la hormona de crecimiento en deficiencias diagnosticadas; los productos aprobados requieren receta y tienen indicaciones definidas.
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Amounts, timing and cycles
Approved medicine
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Amount status
Only the prescribing information for the exact approved product applies; brands, concentrations and indications are not interchangeable.
Profile evidence level: established.
Timing
Intervals, time of day and missed-dose handling depend on the product and indication.
No individual recommendation.
Cycle/duration
Approved medicines are clinician-managed treatment, not freely designed community cycles.
No individual recommendation.
No matching detail page found in the reference source
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Reconstitución y conversión U-100
No generic calculator
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
Mechanism and research questions
Recombinant human growth hormone acting at the growth-hormone receptor
HGH / Somatropin is classified as “Recombinant human growth hormone acting at the growth-hormone receptor”. Sustituye la hormona de crecimiento en deficiencias diagnosticadas; los productos aprobados requieren receta y tienen indicaciones definidas. This describes the investigated pathway but does not validate a community use, amount, route or combination.
01
Terapia de reemplazo de HGH
Esto estudia la administración directa de hormona del crecimiento recombinante en caso de deficiencia confirmada, de forma similar a reemplazar una sustancia que el cuerpo produce normalmente. Se miden el crecimiento, la composición corporal y los niveles hormonales en estudios clínicos.
02
Amplificación del eje de crecimiento
Los investigadores estudian cómo una sustancia amplifica la cadena hormonal natural desde el cerebro hasta la hipófisis y la hormona del crecimiento, en lugar de suministrar la hormona del crecimiento directamente. Se miden los niveles hormonales a lo largo del tiempo y la masa muscular o grasa.
03
Variante de empalme de IGF-1
Esto estudia cómo una variante producida localmente en el tejido del factor de crecimiento IGF-1 podría estar implicada en la reparación de células musculares, de forma similar a una respuesta regional en lugar de una respuesta corporal general. Se miden el crecimiento celular y los marcadores de reparación en modelos de laboratorio.
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Foros de culturismo
Aquí se comparan el crecimiento muscular, las ganancias de fuerza y los tiempos de recuperación entre diferentes péptidos de crecimiento y reparación, a menudo basándose en registros de entrenamiento personales. Las afirmaciones de proveedores y usuarios sobre las ganancias musculares son experiencias anecdóticas, no resultados de estudios controlados.
Foros antienvejecimiento
Aquí se comparan combinaciones de péptidos del eje de crecimiento, mitocondriales y de la piel con el objetivo de influir en los signos visibles o percibidos del envejecimiento, a menudo documentados personalmente durante años. Las anécdotas y la publicidad de proveedores sobre el envejecimiento ralentizado no son una prueba científica.
Discusión de origen y pureza
Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.
Adverse effects and risk boundaries
Interferir con los ejes de GH, IGF-1 u otras hormonas puede causar edema, molestias articulares o nerviosas, intolerancia a la glucosa y cambios de presión u hormonales; faltan datos humanos fiables para muchas sustancias.
Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
Cáncer activo o previo, diabetes no controlada, enfermedad intracraneal, embarazo/lactancia y trastornos hormonodependientes exigen valoración especializada; los productos aprobados tienen contraindicaciones específicas.
Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
En un uso médicamente justificado pueden ser relevantes IGF-1, glucosa en ayunas/HbA1c, presión, peso/edema, tiroides y hormonas específicas; no es un esquema de autoanálisis.
Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
Establecido
Los productos aprobados son de venta bajo receta y se limitan a condiciones de deficiencia definidas.
Published evidence
La función biológica descrita está bien establecida o existen amplios datos humanos revisados por autoridades para productos y usos claramente definidos. Esto no se transfiere automáticamente a otros productos o fines.
La somatropina es la propia hormona del crecimiento recombinante, mientras que secretagogos como la sermorelina solo estimulan la liberación propia del cuerpo.
Storage and stability
The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
Aprobado para usos específicos
Principio activo con receta para indicaciones definidas en al menos una jurisdicción; aquí no se ofrece.
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.